InvestorsHub Logo
Followers 132
Posts 6427
Boards Moderated 0
Alias Born 05/13/2014

Re: aGuyUS post# 25433

Wednesday, 10/07/2020 1:06:45 PM

Wednesday, October 07, 2020 1:06:45 PM

Post# of 44690
Thanks for posting. So here we are with Bachem ... amazing.. Good reminder of where this drug is coming from and how it will be rolled out. May 14th press on Bachem... grabbed this quickly from Andy2018’s August post (linked below):



GENEVA and RADNOR, PA., May 14, 2020 – RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. announced today that NeuroRx has completed final manufacturing of investigational drug RLF-100 for Phase 2b/3 clinical trial to assess intravenous RLF-100 as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients on mechanical ventilation.

Bachem Americas (Torrance, Calif.) and MedisourceRx (Encinatas, Calif.) respectively manufactured RLF-100 drug substance and drug product under the supervision of NeuroRx scientists Richard Siegel, Ph.D., and Robert Besthof MIM who previously held leadership positions at Johnson & Johnson and Pfizer prior to joining NeuroRx. Manufacture and release of investigational product was completed within 60 days of FDA’s approval to proceed with the clinical trial.

MedisourceRx (Encinatas, Calif.)
https://www.medisourcerx.com/news


Bachem Americas (Torrance, Calif.)
https://www.bachem.com/news-media/press-releases/


https://relieftherapeutics.com/relief-therapeutics-and-neurorx-announce-final-manufacturing-validation-of-rlf-100-for-phase-2b3-clinical-trial-in-patients-with-covid-19-associated-acute-respiratory-distress-syndrome/






https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157470773